Edesa Biotech (EDSA) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed NextCure (NXTC) over the past year, gaining 17.6% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -95.6% for EDSA. NextCure is the larger company by market cap ($29.5 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | NXTC |
|---|---|---|
| Share price | $2.00 | $6.45 |
| Market cap | $27.02M | $29.53M |
| 1-day change | -8.05% | -4.87% |
| YTD return | +40.85% | -54.55% |
| 1-year return | +17.65% | -38.63% |
| 5-year return | -95.63% | -91.07% |
| EPS (TTM) | $-1.72 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.19M | $-55.84M |
| 52-week high | $20.32 | $15.74 |
| 52-week low | $0.72 | $1.55 |
| Distance from 52-week high | -90.16% | -59.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +716.50% | +210.08% |
| Average volume | 1.45M | 79.46K |
| Shares outstanding | 13.51M | 4.58M |
| Employees | 17 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed NXTC by 56.3 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
EDSA vs NXTC FAQ
Which is bigger, Edesa Biotech or NextCure?
NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or NXTC?
EDSA returned +17.65% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.